Mesoblast (MESO) Cash & Equivalents Growth (5y) (2020 - 2025)

Mesoblast (MESO) Cash & Equivalents Growth (5y) (2020 - 2025) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Mesoblast 19.81 Bn 19.68 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2025 10.89%
Jun 30, 2025 4.55%
Dec 31, 2024 -14.11%
Jun 30, 2024 4.54%
Dec 31, 2023 0.14%
Jun 30, 2023 13.56%
Mar 31, 2023 -3.90%
Dec 31, 2022 7.37%
Sep 30, 2022 6.32%
Jun 30, 2022 5.72%
Mar 31, 2022 2.12%
Dec 31, 2021 22.85%
Jun 30, 2021 11.08%
Dec 31, 2020 -8.49%
Jun 30, 2020 3.16%